Trial Profile
An open, randomised, parallel-group study evaluating the exposure of and safety of O304 Na-salt and in combination with dapagliflozin (Forxiga) in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2020
Price :
$35
*
At a glance
- Drugs ATX 304 (Primary) ; Dapagliflozin (Primary)
- Indications Metabolic disorders; Renal failure; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Betagenon
- 20 Aug 2020 New trial record
- 17 Aug 2020 According to a Betagenon media release, Status changed from planning to recruiting.
- 17 Aug 2020 According to a Betagenon media release, approvals from the Medicine Product Agency, Sweden, and the Ethics committee to conduct the clinical study have recently been granted.